144 related articles for article (PubMed ID: 17536796)
21. Effects of thyroid hormones on basal and stimulated gastric acid secretion due to histamine, carbachol and pentagastrin in rats.
Rafsanjani FN; Z Asl S; Naseri MK; Vahedian J
Saudi Med J; 2003 Apr; 24(4):341-6. PubMed ID: 12754530
[TBL] [Abstract][Full Text] [Related]
22. GABAA receptor pharmacology of fluorinated derivatives of the novel sedative-hypnotic pyrazolopyrimidine indiplon.
Wegner F; Deuther-Conrad W; Scheunemann M; Brust P; Fischer S; Hiller A; Diekers M; Strecker K; Wohlfarth K; Allgaier C; Steinbach J; Hoepping A
Eur J Pharmacol; 2008 Feb; 580(1-2):1-11. PubMed ID: 18035350
[TBL] [Abstract][Full Text] [Related]
23. Thermodynamic analysis does not allow discrimination of agonists and antagonists at human CCK2S-receptors.
Harper EA; Mitchell EA; Griffin EP; Kalindjian SB
Eur J Pharmacol; 2008 Feb; 581(1-2):1-12. PubMed ID: 18158148
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
25. TGF-beta3 inhibits pentagastrin-stimulated gastric acid secretion in rats.
Beckert S; Wolf SC; Farrahi F; Zittel TT; Coerper S
Med Sci Monit; 2005 Mar; 11(3):BR80-3. PubMed ID: 15735558
[TBL] [Abstract][Full Text] [Related]
26. Peripheral dopamine D2-like receptors have a regulatory effect on carbachol-, histamine- and pentagastrin-stimulated gastric acid secretion.
Eliassi A; Aleali F; Ghasemi T
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1065-70. PubMed ID: 18505447
[TBL] [Abstract][Full Text] [Related]
27. Benzodiazepines as potent and selective bradykinin B1 antagonists.
Wood MR; Kim JJ; Han W; Dorsey BD; Homnick CF; DiPardo RM; Kuduk SD; MacNeil T; Murphy KL; Lis EV; Ransom RW; Stump GL; Lynch JJ; O'Malley SS; Miller PJ; Chen TB; Harrell CM; Chang RS; Sandhu P; Ellis JD; Bondiskey PJ; Pettibone DJ; Freidinger RM; Bock MG
J Med Chem; 2003 May; 46(10):1803-6. PubMed ID: 12723943
[TBL] [Abstract][Full Text] [Related]
28. N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Mori H; Tonai-Kachi H; Ochi Y; Taniguchi Y; Ohshiro H; Takahashi N; Aihara T; Hirao A; Kato T; Sakakibara M; Kurebayashi Y
J Pharmacol Exp Ther; 2009 Feb; 328(2):671-9. PubMed ID: 18981288
[TBL] [Abstract][Full Text] [Related]
29. Characterization of [3H]pentagastrin binding in guinea pig gastric glands--an alternative convenient ligand for receptor binding assay.
Chang RS; Lotti VJ; Keegan ME; Kunkel KA
Biochem Biophys Res Commun; 1986 Jan; 134(2):895-9. PubMed ID: 3004471
[TBL] [Abstract][Full Text] [Related]
30. Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.
Kalindjian SB; Buck IM; Davies JM; Dunstone DJ; Hudson ML; Low CM; McDonald IM; Pether MJ; Steel KI; Tozer MJ; Vinter JG
J Med Chem; 1996 Apr; 39(9):1806-15. PubMed ID: 8627604
[TBL] [Abstract][Full Text] [Related]
31. Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
Padia JK; Field M; Hinton J; Meecham K; Pablo J; Pinnock R; Roth BD; Singh L; Suman-Chauhan N; Trivedi BK; Webdale L
J Med Chem; 1998 Mar; 41(7):1042-9. PubMed ID: 9544204
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.
Woltering TJ; Wichmann J; Goetschi E; Adam G; Kew JN; Knoflach F; Ballard TM; Huwyler J; Mutel V; Gatti S
Bioorg Med Chem Lett; 2008 Apr; 18(8):2725-9. PubMed ID: 18374569
[TBL] [Abstract][Full Text] [Related]
33. Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
Low CM; Buck IM; Cooke T; Cushnir JR; Kalindjian SB; Kotecha A; Pether MJ; Shankley NP; Vinter JG; Wright L
J Med Chem; 2005 Nov; 48(22):6790-802. PubMed ID: 16250638
[TBL] [Abstract][Full Text] [Related]
34. Developments in the inhibition of gastric acid secretion.
Mössner J; Caca K
Eur J Clin Invest; 2005 Aug; 35(8):469-75. PubMed ID: 16101666
[TBL] [Abstract][Full Text] [Related]
35. Synergistic action of gastrin and ghrelin on gastric acid secretion in rats.
Fukumoto K; Nakahara K; Katayama T; Miyazatao M; Kangawa K; Murakami N
Biochem Biophys Res Commun; 2008 Sep; 374(1):60-3. PubMed ID: 18611393
[TBL] [Abstract][Full Text] [Related]
36. Effect of free dietary glutamate on gastric secretion in dogs.
Zolotarev V; Khropycheva R; Uneyama H; Torii K
Ann N Y Acad Sci; 2009 Jul; 1170():87-90. PubMed ID: 19686114
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.
Akgün E; Körner M; Gao F; Harikumar KG; Waser B; Reubi JC; Portoghese PS; Miller LJ
J Med Chem; 2009 Apr; 52(7):2138-47. PubMed ID: 19271701
[TBL] [Abstract][Full Text] [Related]
38. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological comparison of the alternatively spliced short and long CCK2 receptors.
Morton MF; Harper EA; Tavares IA; Shankley NP
Br J Pharmacol; 2003 Sep; 140(1):218-24. PubMed ID: 12967952
[TBL] [Abstract][Full Text] [Related]
40. Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.
Elliott RL; Cameron KO; Chin JE; Bartlett JA; Beretta EE; Chen Y; Jardine Pda S; Dubins JS; Gillaspy ML; Hargrove DM; Kalgutkar AS; LaFlamme JA; Lame ME; Martin KA; Maurer TS; Nardone NA; Oliver RM; Scott DO; Sun D; Swick AG; Trebino CE; Zhang Y
Bioorg Med Chem Lett; 2010 Nov; 20(22):6797-801. PubMed ID: 20851601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
